Integral analysis of p53 and its value as prognostic factor in sporadic colon cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Fariña Sarasqueta, Arantza ^a   Forte, Giusi ^a   Corver, Wim E ^a   de Miranda, Noel F ^a   Ruano, Dina ^a   van Eijk, Ronald ^a   Oosting, Jan ^a   Tollenaar, Rob A E M ^a   van Wezel, Tom ^a   Morreau, Hans ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Colon cancer; CSKN1A1; P53; Prognosis; Survival

Indexed keywords

CASEIN KINASE IALPHA; DNA; MESSENGER RNA;

ADULT; AGED; ALLELE; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; CSNK1A1 GENE; EXON; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE INACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE; TUMOR CELL; TUMOR GENE; TUMOR INVASION;

EID: 84878461684     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-277     Document Type: Article

References (38)

1. Cho KR, Vogelstein B. Genetic alterations in the adenoma-carcinoma sequence. Cancer 1992, 70(6 Suppl):1727-1731.
2. Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 2002, 14(1):86-91. 10.1097/00001622-200201000-00015, 11790986.
3. Elyada E, Pribluda A, Goldstein RE, Morgenstern Y, Brachya G, Cojocaru G, Snir-Alkalay I, Burstain I, Haffner-Krausz R, Jung S, et al. CKIalpha ablation highlights a critical role for p53 in invasiveness control. Nature 2011, 470(7334):409-413. 10.1038/nature09673, 21331045.
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991, 253:49-53. 10.1126/science.1905840, 1905840.
5. Baretton GB, Vogt M, Muller C, Diebold J, Schneiderbanger K, Schmidt M, Lohrs U. Prognostic significance of p53 expression, chromosome 17 copy number, and DNA ploidy in non-metastasized colorectal carcinomas (stages IB and II). Scand J Gastroenterol 1996, 31(5):481-489. 10.3109/00365529609006769, 8734346.
6. Bazan V, Migliavacca M, Zanna I, Tubiolo C, Corsale S, Calo V, Amato A, Cammareri P, Latteri F, Grassi N, et al. DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study. J Cancer Res Clin Oncol 2002, 128(12):650-658. 10.1007/s00432-002-0394-6, 12474051.
7. Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Hermans J, Buys CC, Plukker JT. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer. Am J Gastroenterol 2000, 95(10):2953-2957. 10.1111/j.1572-0241.2000.02327.x, 11051374.
8. Bouzourene H, Gervaz P, Cerottini JP, Benhattar J, Chaubert P, Saraga E, Pampallona S, Bosman FT, Givel JC. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 2000, 36(8):1008-1015. 10.1016/S0959-8049(00)00036-8, 10885605.
9. Chang S-C, Lin J-K, Yang SH, Wang H-S, Li AF-Y, Chi C-W. Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer 2006, 118:1721-1717. 10.1002/ijc.21563, 16231316.
10. Clausen OP, Lothe RA, Borresen-Dale AL, De Angelis P, Chen Y, Rognum TO, Meling GI. Association of p53 accumulation with TP53 mutations, loss of heterozygosity at 17p13, and DNA ploidy status in 273 colorectal carcinomas. Diagn Mol Pathol 1998, 7(4):215-223. 10.1097/00019606-199808000-00006, 9917132.
11. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 2005, 54(9):1283-1286. 10.1136/gut.2005.066514, 1774675, 15843421.
12. Elsaleh H, Powel B, McCaul K, Grieu F, Grant R, Joseph D, Iacopetta B. p53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 2001, 7:1343-1349.
13. Goh H-S, Chan C-S, Khine K, Smith DR. p53 and the behaviour of colorectal cancer. Lancet 1994, 344:233-234. 10.1016/S0140-6736(94)93000-7, 7913159.
14. Goh H-S, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995, 55:5217-5221.
15. Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T, Kerr D, Elsaleh H, Soong R, Kandioler D, et al. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol 2006, 17(5):842-847. 10.1093/annonc/mdl035, 16524972.
16. Munro AJ, Lain S, Lane DP. p53 abnormalities and outcomes in colorectal cancer:a systematic review. Br J Cancer 2005, 92:434-444. 2362083, 15668707.
17. Russo A, Bazan V, Agense V, Rodolico V, Gebbia N. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 2005, 16(4):iv44-iv49.
18. Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 2008, 57(7):941-950. 10.1136/gut.2007.135004, 18364437.
19. Westra JL, Boven LG, van der Vlies P, Faber H, Sikkema B, Schaapveld M, Dijkhuizen T, Hollema H, Buys CH, Plukker JT, et al. A substantial proportion of microsatellite-unstable colon tumors carry TP53 mutations while not showing chromosomal instability. Genes Chromosomes Cancer 2005, 43(2):194-201. 10.1002/gcc.20148, 15729700.
20. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 1998, 17(16):4657-4667. 10.1093/emboj/17.16.4657, 1170795, 9707425.
21. Lynch CJ, Milner J. Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency. Oncogene 2006, 25(24):3463-3470. 10.1038/sj.onc.1209387, 16449974.
22. Yoon H, Liyanarachchi S, Wright FA, Davuluri R, Lockman JC, de la Chapelle A, Pellegata NS. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc Natl Acad Sci USA 2002, 99(24):15632-15637. 10.1073/pnas.242597299, 137768, 12438652.
23. Corver WE, Middeldorp A, ter Haar NT, Jordanova ES, van Puijenbroek M, van Eijk R, Cornelisse CJ, Fleuren GJ, Morreau H, Oosting J, et al. Genome-wide allelic state analysis on flow-sorted tumor fractions provides an accurate measure of chromosomal aberrations. Cancer Res 2008, 68(24):10333-10340. 10.1158/0008-5472.CAN-08-2665, 19074902.
24. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, et al. Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer. J Clin Oncol 2011, 29(1):17-24. 10.1200/JCO.2010.30.1077, 21098318.
25. Bosman F, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system 2010, Lyon, France: International Agency for Research on Cancer (IARC), Fourth, Chapter 8; 134-146.
26. Corver WE, ter Haar NT. High-resolution multiparameter DNA flow cytometry for the detection and sorting of tumor and stromal subpopulations from paraffin-embedded tissues. Curr Protoc Cytom 2011, 7(7):37.
27. Corver WE, Ter Haar NT, Dreef EJ, Miranda NF, Prins FA, Jordanova ES, Cornelisse CJ, Fleuren GJ. High-resolution multi-parameter DNA flow cytometry enables detection of tumour and stromal cell subpopulations in paraffin-embedded tissues. J Pathol 2005, 206(2):233-241. 10.1002/path.1765, 15822070.
28. Lips EH, van Eijk R, de Graaf EJ, Doornebosch PG, de Miranda NF, Oosting J, Karsten T, Eilers PH, Tollenaar RA, van Wezel T, et al. Progression and tumor heterogeneity analysis in early rectal cancer. Clin Cancer Res 2008, 14(3):772-781. 10.1158/1078-0432.CCR-07-2052, 18245538.
29. Middeldorp A, van Eijk R, Oosting J, Forte GI, van Puijenbroek M, van Nieuwenhuizen M, Corver WE, Ruano D, Caldes T, Wijnen J, et al. Increased frequency of 20q gain and copy-neutral loss of heterozygosity in mismatch repair proficient familial colorectal carcinomas. Int J Cancer 2011,
30. Cruz I, Snijders PJ, Van Houten V, Vosjan M, Van der Waal I, Meijer CJ. Specific p53 immunostaining patterns are associated with smoking habits in patients with oral squamous cell carcinomas. J Clin Pathol 2002, 55(11):834-840. 10.1136/jcp.55.11.834, 1769794, 12401821.
31. Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier P, Schneider U, et al. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2009, 15(12):4191-4198. 10.1158/1078-0432.CCR-08-3297, 19509155.
32. Hosmer DW, Lemeshow S. Applied survival analysis. Regression modelling of time to event data 1999, New York: John Wiley & Sons, INC.
33. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:3.
34. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007, 8(4):275-283. 10.1038/nrm2147, 17380161.
35. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009, 137(3):413-431. 10.1016/j.cell.2009.04.037, 19410540.
36. Zuckerman V, Wolyniec K, Sionov RV, Haupt S, Haupt Y. Tumour suppression by p53: the importance of apoptosis and cellular senescence. J Pathol 2009, 219(1):3-15.
37. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002, 108(6):837-847. 10.1016/S0092-8674(02)00685-2, 11955436.
38. Markl B, Renk I, Oruzio DV, Jahnig H, Schenkirsch G, Scholer C, Ehret W, Arnholdt HM, Anthuber M, Spatz H. Tumour budding, uPA and PAI-1 are associated with aggressive behaviour in colon cancer. J Surg Oncol 2010, 102(3):235-241. 10.1002/jso.21611, 20740581.